{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:48:51Z","timestamp":1788306531885,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.juro.2007.05.029","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T07:18:31Z","timestamp":1184656711000},"page":"849-853","source":"Crossref","is-referenced-by-count":70,"title":["Serum Bone Turnover Markers (PINP and ICTP) for the Early Detection of Bone Metastases in Patients With Prostate Cancer: A Longitudinal Approach"],"prefix":"10.1097","volume":"178","author":[{"given":"N.","family":"Koopmans","sequence":"first","affiliation":[{"name":"Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.J.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Breeuwsma","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van der Veer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2007.05.029_bib1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1595::AID-CNCR10>3.0.CO;2-V","article-title":"Radiologic diagnosis of bone metastases","volume":"80","author":"Rosenthal","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2007.05.029_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.20314","article-title":"Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications","volume":"111","author":"Jung","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2007.05.029_bib3","first-page":"152","article-title":"A review of the efficacy of bone scanning in prostate and breast cancer","volume":"46","author":"O\u2019Sullivan","year":"2002","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.juro.2007.05.029_bib4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2007.05.029_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<1::AID-PROS1>3.0.CO;2-X","article-title":"Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer","volume":"39","author":"Koga","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2007.05.029_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410x.2001.00105.x","article-title":"The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone","volume":"87","author":"Koizumi","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2007.05.029_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s007740170059","article-title":"Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy","volume":"19","author":"Tamada","year":"2001","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.juro.2007.05.029_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/bjc.1995.204","article-title":"Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer","volume":"71","author":"Kylmala","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2007.05.029_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0022-5347(05)65930-7","article-title":"Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer","volume":"166","author":"Noguchi","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.05.029_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.05.029_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.urology.2004.03.012","article-title":"Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer","volume":"64","author":"Miyaji","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.05.029_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2007.05.029_bib13","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2007.05.029_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.05.029_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/pros.20540","article-title":"Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer","volume":"67","author":"Ramankulov","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2007.05.029_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2007.02.033","article-title":"Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression","author":"Lein","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.05.029_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.juro.2007.05.029_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1745-7262.2007.00226.x","article-title":"Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells","volume":"9","author":"Li","year":"2007","journal-title":"Asian J Androl"},{"key":"10.1016\/j.juro.2007.05.029_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pros.20311","article-title":"Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma","volume":"66","author":"Brasso","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2007.05.029_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534707012384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534707012384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2007.05.029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:51:23Z","timestamp":1784908283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.juro.2007.05.029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1016\/j.juro.2007.05.029"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2007.05.029","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}